Avalo Therapeutics (NASDAQ:AVTX) Sees Large Volume Increase Following Analyst Upgrade

Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares saw an uptick in trading volume on Thursday after Citizens Jmp raised their price target on the stock from $52.00 to $62.00. Citizens Jmp currently has a market outperform rating on the stock. 1,699,078 shares traded hands during trading, an increase of 85% from the previous session’s volume of 916,530 shares.The stock last traded at $22.55 and had previously closed at $21.81.

A number of other equities research analysts also recently weighed in on the company. Guggenheim began coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday. Wedbush lifted their price target on shares of Avalo Therapeutics from $29.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, BTIG Research lifted their price target on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.14.

Insider Activity at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at $58,495.30. The trade was a 87.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher Ryan Sullivan sold 8,458 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total transaction of $110,715.22. Following the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at approximately $116,239.20. This represents a 48.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 63,015 shares of company stock valued at $987,326. Company insiders own 4.46% of the company’s stock.

Key Stories Impacting Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Positive Phase 2 LOTUS topline results — the LOTUS trial met its primary endpoint (HiSCR75 at Week 16) at both doses and showed benefits on key secondary endpoints; Avalo said it will advance abdakibart into a registrational Phase 3 program, which materially de‑risks the program and supports higher long‑term commercial potential. Read More.
• Positive Sentiment: Large $375M public offering priced to fund development — Avalo priced ~19.73M shares (plus pre‑funded warrants) at $17.75 to raise gross proceeds of ~$375M; management says proceeds will support abdakibart’s Phase 3 and general corporate purposes, strengthening the company’s cash runway. Read More.
• Positive Sentiment: Analyst upgrades and higher targets — several firms raised ratings/targets (examples: BTIG to $58, Citizens JMP to $62, Wedbush to $40), reflecting renewed bullishness post‑data and likely contributing to buying interest. Read More.
• Neutral Sentiment: Market reaction / transaction timing — the offering is expected to close subject to customary conditions (expected May 7), and the underwriters have a 30‑day option to buy additional shares; near‑term trading will reflect both the data and final closing details. Read More.
• Negative Sentiment: Dilution and potential near‑term selling pressure — the sizable equity raise will dilute existing shareholders and could cap the stock until proceeds are deployed and Phase 3 milestones are achieved. Read More.
• Negative Sentiment: Signatures of hedging / insider activity — reports show unusually large put option activity and recent insider sales (multiple officers selling shares), which investors may interpret as short‑term hedging or tax/liquidity sales and a cautionary indicator for near‑term volatility.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AVTX. BIT Capital GmbH acquired a new position in shares of Avalo Therapeutics in the third quarter valued at approximately $25,000. PFS Partners LLC increased its stake in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares during the period. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the second quarter valued at $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics in the third quarter valued at $143,000. Finally, Jump Financial LLC acquired a new stake in Avalo Therapeutics in the fourth quarter valued at $238,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Price Performance

The firm has a market capitalization of $603.20 million, a price-to-earnings ratio of -3.93 and a beta of 0.78. The stock has a fifty day moving average of $15.47 and a two-hundred day moving average of $16.29.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. On average, research analysts forecast that Avalo Therapeutics, Inc. will post -3.38 EPS for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.